Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032)-Reference-Cited by-同舟云学术

Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032)

Published:2023-11 Issue: Volume:178 Page:161-169
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Randall Leslie M.,O'Malley David M.,Monk Bradley J.,Coleman Robert L.,Gaillard Stephanie,Adams Sarah,Duska Linda R.,Dalton Heather,Holloway Robert W.,Huang Marilyn,Chon Hye Sook,Cloven Noelle G.,ElNaggar Adam C.,O'Cearbhaill Roisin E.,Waggoner Steven,Tarkar Aarti,Striha Alina,Nelsen Linda M.,Baines Amanda,Samnotra Vivek,Konstantinopoulos Panagiotis A.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference39 articles.

1. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Ledermann;Ann. Oncol.,2013

2. Ovarian cancer statistics, 2018;Torre;CA Cancer J. Clin.,2018

3. Cancer statistics, 2021;Siegel;CA Cancer J. Clin.,2021

4. PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis;Lin;BJOG,2021

5. Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives;McClung;Int. J. Women's Health,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer;Journal of Translational Medicine;2024-08-21

2. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial;JCO Precision Oncology;2024-05

3. Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD‐L1, for BRCA wild‐type, platinum‐sensitive, recurrent ovarian cancer;Cancer;2024-01-30